Interview with Melissa Thomas, Managing Director, Nycomed UK Ltd.
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
Address: Takeda House
Mercury Park
Wycombe Lane
Wooburn Green
High Wycombe
Bucks, HP10 0HH
United Kingdom
Tel: +44 (0) 1628 537 900
Web: http://www.takeda.co.uk/uk/
Nycomed is a privately owned, global, market-driven pharmaceutical company with a differentiated portfolio of branded medicines in gastroenterology, respiratory, inflammatory diseases, pain, and osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. With turnover of €3.2 billion in 2009, Nycomed is among the 25 largest pharmaceutical companies in the world and the 15th largest provider of over-the-counter medicines.
In the UK, recent years have seen a dramatic shift in the prescribing landscape. Nycomed UK recognises the need to respond to these significant changes and is committed to adapting its business model to allow it to effectively manage customers’ evolving needs. To this end Nycomed UK has recently introduced a revised model that it believes will allow it to flex and adapt to not only the whole system changes laid out in the recently published White Paper, but also the geographical differences that exist within the NHS. The new structure will provide the platform for national strategies to be implemented through the optimisation of regional opportunities by tailoring the amount and type of resource utilised at a local level as appropriate.
Nycomed markets hospital products throughout Europe and general practitioner and over-the-counter medicines in selected European countries.
Protium> Gastroenterology> Pantoprazole
TachoSil> Tissue Management> 5.5mg fibrinogen/2.0IU thrombin/cm2
Alvesco> Respiratory> Ciclesonide
Preotact> Osteoporosisç> Parathyroid Hormone
Matrifen> Pain Management> Transdermal fentanyl patch
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new…
For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general…
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and…
Karen Osborn, CEO of the International Glaucoma Association, explains the role of the charity, detailing its threefold purpose of funding research, raising awareness and helping patients live with the disease.…
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s…
Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to…
One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical…
Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid…
Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and…
See our Cookie Privacy Policy Here
